Evaluation of allogeneic transplantation in first or later minimal residual disease – negative remission following adult-inspired therapy for acute lymphoblastic leukemia

Ryan D. Cassaday*, D. Alan Potts, Philip A. Stevenson, Merav Bar, George E. Georges, Andrei R. Shustov, Mohamed L. Sorror, Brent L. Wood, Colleen Delaney, Kristine C. Doney, Rainer F. Storb, Brenda M. Sandmaier

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Abstract: Comparisons without hematopoietic cell transplantation (HCT) to myeloablative (MAC) or reduced-intensity HCT (RIC) for adults with acute lymphoblastic leukemia (ALL) in first minimal-residual-disease negative remission (MRDNeg CR1) are limited. Further, the importance of MRDNeg following salvage therapy (MRDNeg CR2+) is unknown. We evaluated 89 patients in MRDNeg CR1 after adult-inspired treatment: 33 received MAC (12 Philadelphia chromosome [Ph]+), 17 received RIC (13 Ph+), and 39 Deferred HCT (3 Ph+). Three-year overall survival (OS) estimates for MAC, RIC, and Deferred HCT were 71%, 69%, and 68%, while 3-year event-free survival (EFS) estimates were 65%, 54%, and 28%, respectively. Further, HCT in MRDNeg CR1 performed similarly to MRDNeg CR2+: 3-year OS estimates were 70% and 69%, and 3-year EFS estimates were 62% and 62%, respectively. In conclusion, adults with ALL in MRDNeg CR1 following adult-inspired therapy had similar OS with or without HCT, and HCT in MRDNeg CR2 + can yield long-term survival.

Original languageEnglish (US)
Pages (from-to)2109-2118
Number of pages10
JournalLeukemia and Lymphoma
Volume57
Issue number9
DOIs
StatePublished - Sep 1 2016

Keywords

  • Chemotherapeutic approaches
  • clinical results
  • lymphoid leukemia
  • marrow and stem cell transplantation
  • neoplasia
  • prognostication

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Evaluation of allogeneic transplantation in first or later minimal residual disease – negative remission following adult-inspired therapy for acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this